This ASX All Ords stock is rocketing 20% after accepting a takeover offer

These two diagnostics companies are planning to merge their operations.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market may be edging lower on Monday but that hasn't stopped one ASX All Ords stock from rocketing.

In morning trade, the Capitol Health Ltd (ASX: CAJ) share price is up 20% to 29.5 cents.

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital

Image source: Getty Images

Why is this ASX All Ords stock rocketing?

Investors have been scrambling to buy the diagnostic imaging modalities provider's shares this morning after it accepted a merger offer from rival Integral Diagnostics Ltd (ASX: IDX).

According to the release, the two parties have entered into a process and exclusivity deed that will see Integral Diagnostics acquire 100% of Capitol Health via a scheme of arrangement.

The offer that was tabled was an implied exchange ratio of 0.12849 Integral Diagnostics shares for every Capitol Health share. Based on Friday's close prices, this equates to an offer of 32.6 cents per share, which represents a 33% premium.

Capitol Health's chair, Andrew Demetriou, commented:

The Indicative Proposal reflects attractive value for Capitol shareholders and the Board has determined that it is in the best interests of shareholders to engage with Integral.

Capitol Health advised that that each director intends to recommend shareholders to vote in favour of the proposed transaction. This is subject to entry into the implementation deed, the absence of a superior proposal, and the independent expert's report.

Not the first offer

The release notes that this indicative proposal was not the first. It follows an unsolicited approach from Integral Diagnostics in late March regarding a potential combination.

However, while that was not accepted, the ASX All Ords stock's board decided that it was in the best interests of shareholders to engage with Integral Diagnostics and provide non-public information on a confidential and non-exclusive basis to conduct a two-way value based due diligence process.

Following the conclusion of the process, Integral Diagnostics submitted the improved indicative proposal, which has now been accepted.

The ASX All Ords stock's managing director, Justin Walter, commented:

Today's proposed merger announcement with Integral, represents an exciting opportunity for all our valued radiologists, technicians, and staff to be part of Australia's largest pure-play publicly listed imaging company.

This opportunity is a result of their dedicated hard work, particularly over the last five years. The merger will create further value for our shareholders by realising significant benefits through scale, enhanced internal capability, and organic growth.

All underpinned by market leading clinical standards and service to our referrers and their patients.

As things stand, Capitol Health shareholders do not need to take any action regarding the proposal. However, the company warned that it cannot be certain that the proposal will result in a binding transaction.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Integral Diagnostics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
Healthcare Shares

Regis Healthcare expects FY26 EBITDA to hit top end of guidance

Regis Healthcare expects top-end FY26 earnings as strong occupancy, RAD inflows, and efficiency gains set a positive outlook.

Read more »

A man holding a cup of coffee puts his thumb up and smiles with a laptop open.
Healthcare Shares

This ASX healthcare stock could be set to rise 50%

This small cap could be one to watch.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.
Healthcare Shares

Up 60%: Why this exciting ASX stock could keep rising

This speculative stock could still have significant upside according to Bell Potter.

Read more »

A person holds their hands up through the middle of a rubber lifesaving ring while swimming in relatively calm conditions at a beach.
Healthcare Shares

Why this ASX healthcare high-flyer just dropped another 9% today

4DMedical shares are sliding again. Here’s what’s behind the drop.

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

Mayne Pharma stock jumps 8% on strong Q3 update. Has it finally bottomed?

Mayne Pharma's share price has rebounded 32% since hitting a five-year low in March.

Read more »

A young woman sits with her hand to her chin staring off to the side thinking about her investments.
Healthcare Shares

Down 65%, are Cochlear shares a once-in-a-decade buying opportunity?

After a brutal drop, sentiment has turned negative. But looking beyond the next year, the long-term story may still be…

Read more »